The case for assessing cannabidiol in epilepsy

Authors: Maria Roberta Cilio, Elizabeth A. Thiele, Orrin Devinsky
Epilepsia, June 2014

Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the ma…

Cannabinoids for epilepsy.

Authors: David Gloss, Barbara Vickrey
Cochrane Database of Systematic Reviews, 5 March 2014

BACKGROUND: Marijuana appears to have anti-epileptic effects in animals. It is not currently known if it is effective in patients with epilepsy. Some states in the United States of America have explicitly approved its use for epilepsy. OBJECTIVES: To assess the efficacy and sa…

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Authors: Brenda E. Porter, Catherine Jacobson
Epilepsy & Behavior, December 2013

Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in ch…

The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.

Authors: Melisa J. Wallace, Robert E. Blair, Katherine W. Falenski, Billy R. Martin, Robert J. DeLorenzo
Journal of Pharmacology and Experimental Therapeutics, October 2003

Several lines of evidence suggest that cannabinoid compounds are anticonvulsant. However, the anticonvulsant potential of cannabinoids and, moreover, the role of the endogenous cannabinoid system in regulating seizure activity has not been tested in an in vivo model of epileps…

Response to Early AED Therapy and Its Prognostic Implications.

Authors: Jacqueline A. French
Epilepsy Currents, May 2002

Determining the prognosis of patients when they first present with epilepsy is a difficult task. Several clinical studies have shed light on this very important topic. Potential predictors of the refractory state, including seizure etiology, duration of epilepsy before treatme…

Hypnotic and antiepileptic effects of cannabidiol.

Authors: Elisaldo A. Carlini, Jomar M. Cunha
The Journal of Clinical Pharmacology, August-September 1981

Clinical trials with cannabidiol (CBD) in healthy volunteers, isomniacs, and epileptic patients conducted in the authors’ laboratory from 1972 up to the present are reviewed. Acute doses of cannabidiol ranging from 10 to 600 mg and chronic administration of 10 mg for 20 days o…

Chronic administration of cannabidiol to healthy volunteers and epileptic patients.

Authors: Jomar M. Cunha, E.A. Carlini, Aparecido E. Pereira, Oswaldo L. Ramos, Camilo Pimentel, et al
Pharmacology, 1980

In phase 1 of the study, 3 mg/kg daily of cannabidiol (CBD) was given for 30 days to 8 health human volunteers. Another 8 volunteers received the same number of identical capsules containing glucose as placebo in a double-blind setting. Neurological and physical examinations…